AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35931600 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate medical treatment (IMT) started less than 3 months after metastatic diagnosis
Number of subjects: 90
Study 35931600 — intervention group
Group type: COMPARATOR
Intervention: Delayed medical treatment (DMT)
Number of subjects: 90
Study 35931600 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment of metastasis (LTM)
Number of subjects: 90
Study 35931943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib 300 mg dose
Number of subjects: 0
Study 35931943 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state tucatinib
Number of subjects: 0
Study 35931943 — intervention group
Group type: COMPARATOR
Intervention: Tucatinib
Number of subjects: 0
Study 35932306 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow concentrate (BMC)
Number of subjects: 65
Study 35932306 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC injections with higher CFU-F concentrations
Number of subjects: 65
Study 35932313 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the Eustachian tube (BDET)
Number of subjects: 28
Study 35932387 — intervention group
Group type: EXPERIMENTAL
Intervention: Envafolimab 1.0 mg/kg, 2.5 mg/kg, and 5.0 mg/kg SC QW (10 patients)
Number of subjects: 35
Study 35932387 — intervention group
Group type: EXPERIMENTAL
Intervention: Envafolimab 2.5 mg/kg and 5.0 mg/kg SC Q2W (16 patients)
Number of subjects: 35
Study 35932387 — intervention group
Group type: EXPERIMENTAL
Intervention: Envafolimab 300 mg SC Q4W (9 patients)
Number of subjects: 35
Study 35932387 — intervention group
Group type: EXPERIMENTAL
Intervention: Envafolimab
Number of subjects: 35
Study 35932388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat (50 mg/m)
Number of subjects: 0
Study 35932388 — intervention group
Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 0
Study 35932543 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation exposure
Number of subjects: 0
Study 35932543 — intervention group
Group type: EXPERIMENTAL
Intervention: Other exposures (rural exposures, pesticide exposures)
Number of subjects: 0
Study 35932628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib treatment
Number of subjects: 48
Study 35932876 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal cervical length screening program
Number of subjects: 3468
Study 35932876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length screening
Number of subjects: 3468
Study 35932876 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic short cervix treatment (200 mg vaginal progesterone, cerclage, or pessary)
Number of subjects: 3468
Study 35932876 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHOCOL cohort
Number of subjects: 3468
Study 35932937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nēsos wearable, non-invasive, transcutaneous auricular vagus nerve stimulation (taVNS) system
Number of subjects: 25
Study 35932960 — intervention group
Group type: COMPARATOR
Intervention: PDT only (20% ALA, 15 min; blue light 417 nm, 30 min)
Number of subjects: 66
Study 35932960 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT with sandpaper curettage
Number of subjects: 66
Study 35933358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment 2 g/kg monthly for three months
Number of subjects: 10
Study 35933434 — intervention group
Group type: EXPERIMENTAL
Intervention: L2P2 writing intervention (three 7-min sessions over 5 weeks)
Number of subjects: 20
Study 35933434 — intervention group
Group type: EXPERIMENTAL
Intervention: L2P2 writing intervention
Number of subjects: 20
Study 35933552 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 0
Study 35933552 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 0
Study 35933552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35933560 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-messaging intervention for unhealthy alcohol use (UAU)
Number of subjects: 11000
Study 35933560 — intervention group
Group type: COMPARATOR
Intervention: Implementation strategy for text-messaging intervention
Number of subjects: 11000
Study 35933915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobicistat co-administration with osimertinib
Number of subjects: 11
Study 35933915 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib alone
Number of subjects: 11
Study 35934010 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg IV) plus tremelimumab (75 mg IV) for four cycles, followed by durvalumab alone every 4 weeks for up to 12 months.
Number of subjects: 62
Study 35934010 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 62
Study 35934286 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-induction fecal calprotectin (FCP) concentration of ≤250 μg/g
Number of subjects: 1391
Study 35934287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilofexor 100 mg daily
Number of subjects: 47
Study 35934563 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) in female patients
Number of subjects: 1644
Study 35934563 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI) in male patients
Number of subjects: 1644
Study 35934650 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) during laceration repair
Number of subjects: 40
Study 35934726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig20Gly
Number of subjects: 125
Study 35934926 — intervention group
Group type: EXPERIMENTAL
Intervention: ANNE sleep system
Number of subjects: 225
Study 35934926 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 225
Study 35935359 — intervention group
Group type: EXPERIMENTAL
Intervention: Family supportive EOLC intervention group
Number of subjects: 45
Study 35935359 — intervention group
Group type: COMPARATOR
Intervention: Standard EOLC group
Number of subjects: 45
Study 35935379 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA International Registry for PFAPA patients
Number of subjects: 321
Study 35935379 — intervention group
Group type: EXPERIMENTAL
Intervention: Data recruitment through the on-line Research Electronic Data Capture (REDCap) tool
Number of subjects: 321
Study 35935379 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of PFAPA patient's demographics, medical histories, symptoms, triggers/risk factors, therapies, and impact on healthcare systems
Number of subjects: 321
Study 35935445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine (0.75 mg/kg)
Number of subjects: 0
Study 35935445 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (15 mg) and aripiprazole (5 mg)
Number of subjects: 0
Study 35935625 — intervention group
Group type: EXPERIMENTAL
Intervention: HTI assay
Number of subjects: 301
Study 35935625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 301
Study 35935625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 301
Study 35935634 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2i) administered to Group I with inadequately controlled T2D (mean fasting plasma glucose (FPG) of ≥7 mmol/L)
Number of subjects: 450
Study 35935634 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 450
Study 35935634 — intervention group
Group type: COMPARATOR
Intervention: Adequately controlled T2D (mean FPG of <7 mmol/L)
Number of subjects: 450
Study 35935634 — intervention group
Group type: COMPARATOR
Intervention: No diabetes (mean FPG of ≤ 5.5 mmol/L)
Number of subjects: 450
Study 35935714 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition (EEN)
Number of subjects: 0
Study 35935714 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study 35935775 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative hemodynamic optimization protocol based on uncalibrated pulse-contour analysis.
Number of subjects: 172
Study 35935775 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of care (Control group).
Number of subjects: 172
Study 35935785 — intervention group
Group type: EXPERIMENTAL
Intervention: New integrated weaning indices
Number of subjects: 1175
Study 35935821 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus Oxaliplatin
Number of subjects: 0
Study 35935821 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus Oxaliplatin
Number of subjects: 0
Study 35935856 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat Mesylate
Number of subjects: 0
Study 35935856 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir
Number of subjects: 0
Study 35935863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (2 g/day)
Number of subjects: 0
Study 35935863 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35935974 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 Pfizer-BioNTech vaccine
Number of subjects: 150
Study 35936328 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-15 intermittent fitness test
Number of subjects: 32
Study 35936328 — intervention group
Group type: COMPARATOR
Intervention: 2-mile run
Number of subjects: 32
Study 35936702 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 0
Study 35936702 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 35937420 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic adherence monitors with optional SMS messages and alarms
Number of subjects: 51
Study 35937420 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 51
Study 35937495 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 0
Study 35937495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35937937 — intervention group
Group type: COMPARATOR
Intervention: MPG-Luminex Assay
Number of subjects: 110
Study 35937937 — intervention group
Group type: EXPERIMENTAL
Intervention: Anyplex™ II HPV HR Detection assay
Number of subjects: 110
Study 35937937 — intervention group
Group type: EXPERIMENTAL
Intervention: EUROArray HPV Assay
Number of subjects: 110
Study 35938130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg + B vitamins + green tea + rhodiola
Number of subjects: 100
Study 35938130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35938130 — intervention group
Group type: COMPARATOR
Intervention: Rhodiola in isolation
Number of subjects: 100
Study 35938182 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0
Study 35938182 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35938460 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered risk mitigation approaches
Number of subjects: 0
Study 35938460 — intervention group
Group type: EXPERIMENTAL
Intervention: Further research into optimal prevention approaches for CVD among WLWH
Number of subjects: 0
Study 35938545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Androgen Therapy (BAT)
Number of subjects: 0
Study 35938545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Androgen Therapy (BAT) followed by abiraterone or enzalutamide
Number of subjects: 0
Study 35938625 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic shoulder surgery
Number of subjects: 261248
Study 35938625 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenohumeral stabilisation
Number of subjects: 261248
Study 35938625 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen shoulder release
Number of subjects: 261248
Study 35938625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 261248
Study 35938625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary embolism
Number of subjects: 261248
Study 35938625 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation within one year
Number of subjects: 261248
Study 35938625 — intervention group
Group type: EXPERIMENTAL
Intervention: Further surgery for deep infection after rotator cuff repair
Number of subjects: 261248
Study 35938625 — intervention group
Group type: EXPERIMENTAL
Intervention: Further surgery for deep infection overall
Number of subjects: 261248
Study 35938699 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 176
Study 35939260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of quadriceps femoris muscle thickness (MT) in non-contraction (non-con) situation
Number of subjects: 76
Study 35939260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of quadriceps femoris muscle thickness (MT) in contraction (con) situation
Number of subjects: 76
Study 35939260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of muscle echo intensity (MEI) in non-contraction (non-con) situation
Number of subjects: 76
Study 35939260 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood and urinary biomarkers
Number of subjects: 76
Study 35939367 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseizure medications (ASMs)
Number of subjects: 1341509
Study 35939367 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 1341509
Study 35939367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis
Number of subjects: 1341509
Study 35939367 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-drug interactions between ASMs
Number of subjects: 1341509
Study 35939663 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise 3 times a week for 4 weeks
Number of subjects: 24
Study 35939770 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS-based genomic profiling and multidisciplinary case discussions
Number of subjects: 0
Study 35939770 — intervention group
Group type: EXPERIMENTAL
Intervention: WAYFIND-R registry
Number of subjects: 0
Study 35939770 — intervention group
Group type: EXPERIMENTAL
Intervention: User-friendly electronic case report forms and standardized collection of molecular tumor board-based decisions
Number of subjects: 0
Study 35939770 — intervention group
Group type: EXPERIMENTAL
Intervention: Global collaborations between cancer centers
Number of subjects: 0
Study 35939785 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 133
Study 35939812 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Agonist Therapy (OAT)
Number of subjects: 296
Study 35939919 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy program (MTP) applied to craniomandibular structures, four weekly sessions
Number of subjects: 102
Study 35939919 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy program (MTP)
Number of subjects: 102
Study 35939981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion Regression (LR) group
Number of subjects: 161
Study 35939981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion Progression (LP) group
Number of subjects: 161
Study 35940054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A)
Number of subjects: 421
Study 35940054 — intervention group
Group type: COMPARATOR
Intervention: Initial combination of fluoropyrimidine, irinotecan, and bevacizumab (Arm B)
Number of subjects: 421
Study 35940054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment in patients older than 70 years
Number of subjects: 421
Study 35940054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment in patients with RAS mutant tumours
Number of subjects: 421
Study 35940054 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment in RAS/BRAF wild-type tumours
Number of subjects: 421
Study 35940055 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ-B3139 (50-800 mg) administered continuously in 28-day cycles, with expansion stage starting at 200 mg BID.
Number of subjects: 63
Study 35940055 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ-B3139 at dose level ≥200 mg BID.
Number of subjects: 63
Study 35940055 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ-B3139 in patients with measurable brain metastases.
Number of subjects: 63
Study 35940055 — intervention group
Group type: EXPERIMENTAL
Intervention: TKI-treated patients with variant 3 and TP53 alteration.
Number of subjects: 63
Study 35940085 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention (12 sessions over six weeks including bilateral unweighted squats with visual and tactile biofeedback)
Number of subjects: 40
Study 35940085 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (six-week educational program)
Number of subjects: 40
Study 35940183 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus vemurafenib plus cobimetinib
Number of subjects: 65
Study 35940334 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID group
Number of subjects: 0
Study 35940825 — intervention group
Group type: EXPERIMENTAL
Intervention: Varlilumab (0.1-10 mg/kg) with nivolumab (3 mg/kg) administered once every 2 weeks (Phase 1)
Number of subjects: 175
Study 35940825 — intervention group
Group type: EXPERIMENTAL
Intervention: Varlilumab (3 mg/kg once every 2 weeks, 3 mg/kg once every 12 weeks, and 0.3 mg/kg once every 4 weeks) with nivolumab (240 mg once every 2 weeks) (Phase 2)
Number of subjects: 175
Study 35940825 — intervention group
Group type: EXPERIMENTAL
Intervention: Varlilumab and nivolumab combination
Number of subjects: 175
Study 35940836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (up to 20 mg) and glyceryl trinitrate (GTN) (0.8 mg and 0.4 mg)
Number of subjects: 5500
Study 35940836 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced GTN doses
Number of subjects: 5500
Study 35940836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous beta-blocker administration
Number of subjects: 5500
Study 35940836 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN dose reduction
Number of subjects: 5500
Study 35940871 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) applied as four cycles of ischaemia (4 min) followed by reperfusion (4 min) and a 5 min gap, repeated on two consecutive days.
Number of subjects: 15
Study 35941015 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain treatment
Number of subjects: 189
Study 35941023 — intervention group
Group type: EXPERIMENTAL
Intervention: StrataGraft
Number of subjects: 101
Study 35941028 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (loading dose 8 mg/kg, then 6 mg/kg every 3 weeks) and oral pyrotinib (400 mg per day until progression)
Number of subjects: 16
Study 35941028 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and pyrotinib
Number of subjects: 16
Study 35941076 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HBsAg levels
Number of subjects: 344
Study 35941076 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HBV RNA levels
Number of subjects: 344
Study 35941076 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HBcrAg levels
Number of subjects: 344
Study 35941076 — intervention group
Group type: EXPERIMENTAL
Intervention: Flares (defined as ALT ≥5xULN)
Number of subjects: 344
Study 35941212 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose blinatumomab (maximum 112 mcg/d after initial weekly dose escalation) for 8 weeks induction and 4 weeks consolidation.
Number of subjects: 9
Study 35941284 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% peak power output workload
Number of subjects: 12
Study 35941284 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% peak power output workload
Number of subjects: 12
Study 35941284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both workloads
Number of subjects: 12
Study 35941333 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIDE system
Number of subjects: 76
Study 35941333 — intervention group
Group type: COMPARATOR
Intervention: Manual palpation
Number of subjects: 76
Study 35941372 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5.4 mg/kg bodyweight intravenously once every 3 weeks)
Number of subjects: 15
Study 35941514 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTB graft
Number of subjects: 77
Study 35941514 — intervention group
Group type: COMPARATOR
Intervention: Other graft types (hamstring autograft or allografts)
Number of subjects: 77
Study 35941514 — intervention group
Group type: EXPERIMENTAL
Intervention: All graft types
Number of subjects: 77
Study 35941609 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 3 (MMT peel powder)
Number of subjects: 30
Study 35941609 — intervention group
Group type: COMPARATOR
Intervention: Control (glucose)
Number of subjects: 30
Study 35941641 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV after extubation
Number of subjects: 929
Study 35941641 — intervention group
Group type: EXPERIMENTAL
Intervention: CatBoost machine-learning model
Number of subjects: 929
Study 35941653 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional care supported by eHealth (tablet)
Number of subjects: 25
Study 35941653 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth (tablet)
Number of subjects: 25
Study 35941696 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Number of subjects: 28
Study 35941696 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-MSCs
Number of subjects: 28
Study 35941696 — intervention group
Group type: COMPARATOR
Intervention: UC-MSCs and BM-MSCs
Number of subjects: 28
Study 35942082 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ Vivity intraocular lens (DFT015)
Number of subjects: 0
Study 35942082 — intervention group
Group type: COMPARATOR
Intervention: Standard aspheric monofocal intraocular lens (SN60WF)
Number of subjects: 0
Study 35942508 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 in Stage A/B
Number of subjects: 1235
Study 35942508 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 in Stage A/B
Number of subjects: 1235
Study 35942508 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP) in Stage A/B
Number of subjects: 1235
Study 35942508 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP) in Stage C/D
Number of subjects: 1235